Clinical trial · Observational
Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy
Salvage Treatment Strategies and Clinical Outcomes in Diffuse Large B-cell Lymphoma After Failure of Polatuzumab Vedotin-based Combination Therapy: A Multi-center, Retro- and Prospective, Observational, Real-World Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Diffuse Large B-cell Lymphoma (DLBCL) is a common hematologic malignancy. Even after standard first-line treatment, approximately 40% of patients will experience relapse. Currently, polatuzumab vedotin (pola) has been incorporated into DLBCL treatment (both for newly diagnosed and relapsed cases). However, for patients whose disease progresses after pola-containing regimens, the subsequent treatment options, efficacy, and survival outcomes remain unclear. Understanding these real-world scenarios is of great significance, as it can guide clinicians in developing better and more tailored treatment strategies for patients in the future. Therefore, we plan to conduct this real-world study titled "Salvage Treatment Strategies and Clinical Outcomes in Diffuse Large B-cell Lymphoma After Failure of Polatuzumab Vedotin-based Combination Therapy", aiming to obtain real-world data from the Chinese population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma (DLBCL) | Diffuse Large B-Cell Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- complete response rate
- timeFrame
- through study completion, an average of 2 years
- description
- the ratio of patients achieves complete response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with DLBCL * Age ≥18 years * Prior treatment with a polatuzumab vedotin (pola)-containing regimen and confirmed disease progression (refractory/relapsed) after this therapy. * Availability of complete electronic medical records and ability to be contacted via telephone. * Full understanding of the study, voluntary participation, and willingness to sign the informed consent form. Exclusion Criteria: * Patients who have not received pola-based regimen treatment. * Incomplete electronic medical records or unreachable by telephone.
References
Publications (0)
Data not yet available